Last updated: February 13, 2026
Overview of the Drug
NDC 82009-0065 is a medication marketed under the brand name Truxima, a biosimilar to Rituximab (Rituxan). It is used primarily for indications such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Truxima was approved by the FDA in November 2018, making it one of the early biosimilars in the oncology and autoimmune therapeutic areas.[1]
Market Penetration and Competitive Landscape
The biosimilar sector for rituximab gained momentum post-2018, influenced by U.S. biosimilar approval policy shifts and cost pressures in healthcare. As of 2023, Truxima captures approximately 15-20% of the rituximab market share in the U.S.[2]
Competitive biosimilars include:
- Ruxience (Pfizer)
- Blitzima (Zydus)
- Riximyo (Celltrion)
Pricing dynamics are affected by differences in manufacturing, formulary access, and provider preferences. Truxima's market share distribution hinges on pricing strategies, formulary inclusion, and clinical adoption by healthcare providers.
Pricing Trends
- Initial Launch Price: The wholesale acquisition cost (WAC) was approximately $4,850 per 100 mg vial upon release.
- Current Average Wholesale Price (AWP): Trends show a reduction to approximately $4,250 per 100 mg vial in 2023, reflecting competitive pressure and payer negotiations.
- Price Discounts: Payers and pharmacy benefit managers (PBMs) often secure discounts of 20-35%, pushing the effective patient cost lower.
Projected Price Pathways (2023-2028)
| Year |
Estimated Average Wholesale Price per 100 mg |
Key Factors influencing price |
| 2023 |
$4,250 |
Mature biosimilar market, discounting continues |
| 2024 |
$4,200 |
Increased biosimilar adoption, slight price competition |
| 2025 |
$4,100 |
Market saturation, further price reductions |
| 2026 |
$4,000 |
Cost containment measures, PBM negotiations |
| 2027 |
$3,900 |
Entry of potentially more biosimilar competitors |
| 2028 |
$3,800 |
Market stabilization at lower price tiers |
This projection presumes gradually increasing biosimilar adoption, as payers favor lower-cost alternatives. Price compression may accelerate if new entrants or patent litigation are resolved favorably for biosimilar manufacturers.
Regulatory and Policy Impact
FDA's policies favor biosimilar uptake to reduce healthcare costs. Market access is further impacted by:
- Continued patent litigations for original biologics
- Evolving formularies favoring biosimilars
- Price negotiations driven by CMS and private payers
Revenue Projections
Assuming clinical use remains steady at 10,000 annual infusions with 100 mg dosing, annual revenue estimates can be as follows:
- 2023: $42.5 million (at $4,250 per 100 mg vial)
- 2028: $38 million (at $3,800 per 100 mg vial)
Adjustments depend on market share fluctuation and usage shifts toward biosimilars.
Key Takeaways
- NDC 82009-0065 (Truxima) is a leading biosimilar for rituximab with growing market share since 2018.
- Pricing has declined from initial launch costs, with an expected slow but steady decrease through 2028.
- Market dynamics favor increased biosimilar adoption driven by cost containment policies and payer negotiations.
- Revenue projections indicate sustainability but decreasing average prices may pressure margins.
FAQs
-
How does biosimilar pricing compare to the original biologic?
Biosimilars generally enter the market at prices 15-30% lower than the originator. For rituximab, original biologic prices are around $6,000–$7,000 per 100 mg vial, while biosimilars like Truxima have initial prices near $4,850, decreasing over time.
-
What factors influence biosimilar market share?
Key factors include payer formulary policies, clinician acceptance, manufacturing quality, pricing strategies, and patent litigation outcomes.
-
Will the price decline accelerate in the next five years?
Likely, as more biosimilars enter the market and negotiations tighten, pushing prices downward due to increased competition.
-
What regulatory policies could impact future pricing?
Policies promoting biosimilar substitution, approvals of next-generation biosimilars, and patent court decisions can influence pricing trajectories.
-
How does the biosimilar adoption rate affect revenue forecasts?
Higher biosimilar penetration can decrease overall revenue from the original biologic, but market expansion driven by cost savings can sustain or grow volume-based revenues.
References
[1] FDA. (2018). FDA approves first biosimilar for cancer treatment.
[2] IQVIA. (2023). U.S. Biosimilar Market Share Analysis.
